Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 3/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.36 |
| ▸ | PPARG | P37231 | 7/20 | 0.36 |
| ▸ | PPARD | Q03181 | 7/20 | 0.36 |
| ▸ | PPARA | Q07869 | 7/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4293179 | 1.00 | KDM5A (0.36) | KDM5APHF8KDM4CEPHX2GPR84 | |
| Hydrochloric Acid SCHEMBL4290887 | 1.00 | KDM5A (0.36) | KDM5APHF8KDM4CEPHX2GPR84 | |
| SCHEMBL4334125 | 0.99 | KDM5A (0.37) | KDM5APHF8KDM4CEPHX2GPR84 | |
| SCHEMBL4325880 | 0.99 | KDM5A (0.37) | KDM5APHF8KDM4CEPHX2GPR84 | |
| SCHEMBL21048580 | 0.99 | KDM5A (0.37) | KDM5APHF8KDM4CEPHX2GPR84 | |
| Hydrochloric Acid SCHEMBL9330621 | 0.97 | KDM5A (0.36) | KDM5APHF8KDM4CEPHX2GPR84 | |
| Hydrochloric Acid SCHEMBL4302158 | 0.93 | EPHX2 (0.47) | EPHX2PPARGPPARDPPARAPTPN1 | |
| Hydrochloric Acid SCHEMBL15948948 | 0.91 | EPHX2 (0.47) | EPHX2PPARGPPARDPPARAPTPN1 | |
| SCHEMBL4325883 | 0.89 | KDM5A (0.36) | KDM5APHF8KDM4CEPHX2GPR84 | |
| SCHEMBL4334127 | 0.89 | KDM5A (0.36) | KDM5APHF8KDM4CEPHX2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 559 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035723-A1 | Treatment of Pancreatic Cancer | SYNCORE BIOTECHNOLOGY CO., LTD. (TW) | 2023-02-02 | — | — | US | claimed |
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | YALE UNIVERSITY (US) | 2021-11-16 | — | — | US | claimed |
| EP-3397244-B1 | TREATMENT OF BREAST CANCER USING A COMBINATION OF A CATIONIC LIPOSOMAL FORMULATION OF TAXANE, A NON-LIPOSOMAL FORMULATION OF TAXANE AND A FURTHER ACTIVE AGENT | SYNCORE BIOTECHNOLOGY CO LTD (TW) | 2021-10-06 | — | — | EP | claimed |
| EP-3756690-A2 | MEMBRANE-PENETRATING PEPTIDES TO ENHANCE TRANSFECTION AND COMPOSITIONS AND METHODS FOR USING SAME | Life Technologies Corporation (US) | 2020-12-30 | — | — | EP | claimed |
| US-10760098-B2 | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same | Life Technologies Corporation (US) | 2020-09-01 | — | — | US | claimed |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | YALE UNIVERSITY (US) | 2020-07-14 | — | — | US | claimed |
| US-20200179283-A1 | Vehicles For Controlled Delivery of Different Pharmaceutical Agents | NATIONAL SCIENCE FOUNDATION | 2020-06-11 | — | — | US | claimed |
| WO-2019161263-A1 | LIPID-SURFACTANT NANOPARTICLES FOR DRUG DELIVERY AND METHODS OF MAKING AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2019-08-22 | — | — | WO | claimed |
| US-20190209474-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | MODULATE THERAPEUTICS INC (CA) | 2019-07-11 | — | — | US | claimed |
| EP-2836234-B1 | VEHICLES FOR CONTROLLED DELIVERY OF DIFFERENT PHARMACEUTICAL AGENTS | UNIV YALE (US) | 2019-06-12 | — | — | EP | claimed |
| US-7846473-B2 | Irinotecan preparation | TERUMO KABUSHIKI KAISHA (JP) | 2010-12-07 | — | — | US | claimed |
| US-20090319020-A1 | DEVICES, SYSTEMS, AND METHODS FOR PROMOTING ENDOTHELIALIZATION | DTHERAPEUTICS, LLC (US) | 2009-12-24 | — | — | US | claimed |
| WO-2008091569-A2 | DEVICES, SYSTEMS, AND METHODS FOR PROMOTING ENDOTHELIALIZATION | DTHERAPEUTICS, LLC (US) | 2008-07-31 | — | — | WO | claimed |
| US-6726926-B2 | DISACCHARIDE PROTECTOR; FROZEN; PRESERVED FOR LONGER THAN ONE YEAR; SHOWS EXCELLENT RESTORATION ABILITY IN WATER | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2004-04-27 | — | — | US | claimed |
| US-20020044958-A1 | Gene-entrapped liposomes preparation and process fir the preparation thereof | YOSHIDA, JUN (JP) | 2002-04-18 | — | — | US | claimed |
| US-5744159-A | FOR INTRODUCING A GENE INTO CELLS | INSTITUTE OF APPLIED BIOCHEMISTRY GIFU-KEN (JP) | 1998-04-28 | — | — | US | claimed |
| EP-0795325-A1 | Plasmid entrapping multilamellar liposomes | Institute of Applied Biochemistry (JP) | 1997-09-17 | — | — | EP | claimed |
| US-5552157-A | QUATERNARY AMMONIUM LIPIDS | KABUSHIKI KAISHA VITAMIN KENKYUSYA (JP) | 1996-09-03 | — | — | US | claimed |
| EP-0475178-B1 | Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation | VITAMIN KENKYUSHO KK (JP) | 1994-03-30 | — | — | EP | claimed |
| EP-0475178-A1 | Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation | Kabushiki Kaisha Vitamin Kenkyusyo (JP) | 1992-03-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173119-B2 | Nanolipogel vehicles for controlled delivery of different pharmaceutical agents | LIPA, ABCF1, ABCG2 | KDM5A 3994/4885PHF8 2853/4885KDM4C 2434/4885 |
| US-10760098-B2 | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same | SLC7A1, NPC1, NPC1L1 | KDM5A 4510/4885PHF8 2979/4885KDM4C 4343/4885 |
| US-20190209474-A1 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES AND DISORDERS | UACA, HLA-DRB1, TNF | KDM5A 3408/4885PHF8 3013/4885KDM4C 2537/4885 |
| US-20200179283-A1 | Vehicles For Controlled Delivery of Different Pharmaceutical Agents | CETP, HDLBP, ABCG2 | KDM5A 4030/4885PHF8 2634/4885KDM4C 2578/4885 |
| US-10709664-B2 | Nanolipogel comprising a polymeric matrix and a lipid shell | LIPA, CD44, ABCB4 | KDM5A 3387/4885PHF8 3547/4885KDM4C 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.